论文部分内容阅读
为观察白细胞介素４（ＩＬ－４）基因疗法对晚期浆细胞瘤的治疗作用，用成纤维细胞介导的ＩＬ－４基因疗法治疗小鼠Ｊ５５８Ｌ浆细胞瘤，并对其免疫学机制进行了初步探讨。对经治疗小鼠存活期的观察表明，该疗法对早期荷瘤小鼠（荷瘤３天以内）无明显治疗效果；而对晚期荷瘤小鼠（荷瘤１０天以上）则具有较明显的治疗效果；当与常规瘤苗联合应用时其疗效更加明显。对经治疗的荷瘤小鼠体内抗肿瘤免疫功能的检测表明，晚期荷瘤小鼠经ＩＬ－４基因治疗后第１２天，脾细胞ＮＫ活性及经诱导后的ＬＡＫ活性变化不明显，而经诱导的ＣＴＬ杀伤活性明显提高；当与常规瘤苗联合应用时ＣＴＬ杀伤活性的提高更为明显。结果显示，成纤维细胞介导的ＩＬ－４基因疗法主要通过增强ＣＴＬ杀伤活性而对晚期浆细胞瘤小鼠发挥治疗作用。
To observe the therapeutic effect of interleukin-4 (IL-4) gene therapy on advanced plasmacytoma, the mouse J558L plasmacytoma was treated with fibroblast-mediated IL-4 gene therapy and its immunological mechanism was studied Preliminary discussion. The survival of treated mice observed that the treatment of early tumor-bearing mice (tumor-bearing within 3 days) no significant effect; while the late tumor-bearing mice (tumor-bearing more than 10 days) has a more significant Therapeutic effect; when combined with conventional tumor vaccine when the effect is more obvious. The anti-tumor immune function in the treated tumor-bearing mice showed that there was no obvious change in NK activity and induced LAK activity in spleen cells on the 12th day after treatment with IL-4 gene in advanced tumor-bearing mice. Induced CTL killing activity was significantly improved; when combined with conventional tumor vaccine CTL killing activity increased more pronounced. The results show that fibroblast-mediated IL-4 gene therapy plays a therapeutic role in advanced plasmacytoma mice by enhancing CTL cytotoxicity.